While 93 percent of U.S. pediatricians surveyed were aware of the national guidelines on peanut allergy prevention in infants, only 30 percent were fully implementing the recommended practices and 64 percent reported partial implementation, according to the study published in JAMA Network Open.Read more
The University of Chicago Medicine Comer Children’s Hospital was one of the sites for a landmark clinical trial that led to approval of the first oral immunotherapy treatment for peanut allergy in children and teens.Read more
The U.S. Food and Drug Administration (FDA) approved Palforzia, a peanut powder product designed to help reduce peanut-induced allergic reactions.
Although Palforzia just received FDA approval, Nuvance Health allergists/immunologists have been offering oral immunotherapy (OIT) for various food allergies for five years.
By slowly increasing a person’s tolerance to an allergen over time, OIT can lower the risk of having a severe allergic reaction. This lowered risk may help reduce anxiety for kids with food allergies, as well as their family members and caregivers.Read more
Philadelphia, February 3, 2020 – The U.S. Food & Drug Administration (FDA) announced the approval PalforziaTM, a first-of-its-kind treatment forRead more
Nearly 90 percent of peanut-allergic individuals in the study could potentially tolerate almonds, but 33 percent preferred strict avoidance due to fear of an allergic reaction.